Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms explorer8
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 12 Dec 2023 Results (n=148) a 56-weeks cut-off long-term efficacy and safety of daily concizumab prophylaxis in patients with HA/HB, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (cut-off 56-weeks) concizumab effects on target joints,joint bleeds in patients with hemophilia (hemophilia A or B with inhibitors [HAwI or HBwI] or without inhibitors [HA or HB]) from the explorer7 (NCT04083781) and explorer8 (NCT04082429)studies, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 12 Dec 2023 Results(cut-off 56-weeks) assessing patients who received concizumab prophylaxis in the explorer7 and explorer8 trials, presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top